Skip to content. | Skip to navigation


Personal tools

Marcel Bally, Ph.D


A complete list of published work: https://scholar.google.ca/ 


Peer-Reviewed Papers | Non-Peer Reviewed Papers  | Books and Chapters 


Peer-Reviewed Papers


2016

Mu C,  Chang SW, Prosser KE, Leung AW, Santacruz S,  Jang T.  Thompson JR, Yapp DT, Warren JJ, Bally MB, Beischlag TV, and Walsby CJ. Induction of Cytotoxicity in Pyridine Analogues of the Antimetastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization. Inorg Chem. 2016 Jan 4;55(1):177-90. PMID: 26652771

Dragowska WH, Ginj M, Kozlowski P, Yung A, Ruth TJ, Adam MJ, Sossi V, Bally MB and Yapp DT. Overexpression of HER-2 in MDA-MB-435/LCC6 tumors is associated with higher metabolic activity and lower energy stress.  Sci Rep. 2016 Jan 4;6:18537. PMID: 26727049

Wehbe M, Anantha M, Backstrom I, Leung A, Chen K, Malhotra A, Edwards K, Bally M. Nanoscale reaction vessels designed for synthesis of copper-drug complexes suitable for preclinical development. PLoS One. 2016 Apr 7;11(4):e0153416. PMID: 27055237

Leung AWY, Hung SS, Backstrom I, Ricaurte D, Kwok B, Poon S, McKinney S, Segovia R, Rawji J, Qadir MA, Aparicio S, Stirling PC, Steidl C and Bally MB. Combined use of gene expression modeling and siRNA screening identifies genes and pathways which enhance the activity of Cisplatin when added at no effect levels to non-small cell lung cancer cells in vitro. PloS One. 2016 Mar 3;11(3):e0150675. PMID: 26938915.

Wehbe M, Chernov L, Chen K, Bally MB. PRCosomes: pretty reactive complexes formed in liposomes. J Drug Target. 2016 Nov;24(9):787-796. 

Chang SW, Lewis AR, Prosser KE, Thompson JR, Gladkikh M, Bally MB, Warren JJ and Walsby CJ. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity. Inorg Chem. 2016 May 16;55(10):4850-63. PMID: 27143338 

Leung AWY, Backstrom I, and Bally MB. Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer. Oncotarget. 2016 Aug 23;7(34):55811-55827. 

Bortnik S, Choutka C, Horlings HM, Leung S, Baker JH, Lebovitz C, Dragowska WH, Go NE, Bally MB, Minchinton AI, Gelmon KA, Gorski SM.Identification of breast cancer cell subtypes sensitive to ATG4B inhibition. Oncotarget. 2016 Oct 11;7(41):66970-66988. 

Hilchie AL, Sharon AJ, Haney EF, Hoskin DW, Bally MB, Franco OL, Corcoran JA, Hancock RE. Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma. Biochim Biophys Acta. 2016 Dec;1858(12):3195-3204.  

 

2015 

Neijzen R, Wong MQ, Gill N, Wang H, Karim T, Anantha M, Strutt D, Waterhouse D, Bally MB, Tai IT,  Ng SSW and Yapp DT. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer. J Control Release.  2015 Feb 10;199:72-83.  PMID: 25497312 

Kalra J, Dragowska WH and Bally MB. Using Pharmacokinetic profiles and digital quantification of stained tissue microarrays as a medium-throughput, quantitative method of measuring the kinetics of early signaling changes following intergrin-linked kinase inhibition in an in vitro model of cancer. J Histochem Cytochem. 2015 Sep;63(9):691-709. PMID: 25940338 

Leung AW, Dragowska WH, Ricaurte D, Kwok B, Mathew V, Roosendaal J, Ahluwalia A, Warburton C, Laskin JJ, Stirling PC, Qadir MA, and Bally MB. 3'-Phosphoadenosine 5'-Phosphosulfate Synthase 1 (PAPSS1) Knockdown Sensitizes Non-Small Cell Lung Cancer Cells to the DNA Damaging Agents. Oncotarget. 2015 Jul 10;6(19): 17161-77.  PMID 26220590 

Lebovitz CB, DeVorkin L, Bosc D, Rothe K, Singh J, Bally M, Jiang X, Young RN, Lum JL and Gorski SM. Precision autophagy: will the next wave of selective autophagy markers and specific autophagy inhibitors feed clinical pipelines? Autophagy. 2015 Oct 3;11(10):1949-52. PMID: 26506897 

Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT and Bally MB. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. J Control Release. 2015 Dec 28;220(Pt A):348-57. PMID: 26528901  

 

2014

Leung AW, Kalra J, Dos Santos ND, Bally MB and Anglesio MS. Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. Nanomedicine. (Lond). 2014 Mar;9(3):501-22. PMID:24746193

Chittaranjan S, Bortnik S, Dragowska WH, Xu J, Abeysundara N, Leung A, Go NE, DeVorkin L, Weppler SA, Gelmon K, Yapp DT and Bally MB, Gorski SM. Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer. Clin Cancer Res. 2014 Jun 15;20(12):3159-73. PMID:24721646 

Waterhouse DN, Sutherland S, Dos Santos N, Masin D, Osooly M, Strutt D,  Ostlund C, Anantha M, Harasym N, Manisali I, Wehbe M, Bally MB and Webb M. Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.  Invest New Drugs. 2014 Dec;32(6):1071-82. PMID:25064374  

 

2013

Ho EA, Osooly M, Strutt D, Masin D, Yang Y, Yan H and Bally MB. Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor Model. Journal of Pharmaceutical Sciences. 2013;102(1):227-36.  PMID: 23132529

Patankar NA, Pritchard J, Van Grinsven MC, Osooly M and Bally MB. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: The influence of drug exposure time and delivery systems to achieve optimum therapeutic activity. Clinical Cancer Research. 2013;19(4):865-77. PMID: 23303216

Verreault M, Weppler, SA, Stegeman A, Warburton C, Strutt D, Masin D and Bally MB. Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.  PLoS One. 2013;8(3):e59597. PMID: 23555046 

Ahn RW, Barrett SL, Raja MR, Jozefik JK, Sapho L, Chen H and Bally MB, Mazar AP, Avram MJ, Winter JN, Gordon LI, Shea LD, O’Halloran TV, Woodruff TK. Nano-encapsulation of arsenic trioxide enhances efficacy in a murine lymphoma model while minimizing chemotherapeutic fertoxicity in vitro and in vivo. PLoS One. 2013;8(3):e58491. PMID: 23526987 

Hare JI, Neijzen RW, Anantha M, Dos Santos N, Harasym N, Webb MS, Allen TM, Bally MB, Waterhouse DN. Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore CTM) and 5-fluorouracil. PLoS One. 2013 Apr 23;8(4):e62349. PMID: 23626804 

Donohue E, Thomas A, Maurer N, Manisali I, Zeisser-Labouebe M, Zisman N, Anderson HJ, Ng SS, Webb M, Bally M, Roberge M. The Autophagy Inhibitor Verteporfin Moderately Enhances the Antitumor Activity of Gemcitabine in a Pancreatic Ductal Adenocarcinoma Model.  J Cancer. 2013 Aug 8;4(7):585-96. PMID: 24069069 

Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, Roberge M, Gorski SM, Gelmon KA, Bally MB. Induction of Autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One. 2013 Oct 11;8(10):e76503. PMID: 24146879  

 

 2012

Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.  J Controlled Release. 2012 Feb 28;158(1):34-43. PMID: 22001870

Popov J, Kapanen AI, Turner C, Ng R, Tucker C, Chiu G, Klasa R, Bally MB, Chikh G. Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity.  Nanomedicine (Lond). 2011;6(9):1575-91. PMID: 22011314 

Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB. Lipid based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy. Nanomedicine (Lond). 2011;6(9):1645-54. PMID: 22077466 

Patankar NA, Waterhouse D, Strutt D, Anantha M, Bally MB. Topophore C: A liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer  Investigational New Drugs. 2013 Feb;31(1):46-58. PMID: 22615060 

Musende AG, Eberding A, Wood CA, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Tomlinson Guns ES. A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer. Anticancer Drugs. 2012;23(5):543-52. PMID: 22481061       

 

2011

Patankar N, Anantha M, Ramsay E, Waterhouse D, Bally M. The role of the transition metal copper and the ionophore A23187 in the development of irinophore CTM. Pharm Res. 2011 Apr;28(4):848-57. PMID: 21181548 

Thomas AM, Kapanen AI, Hare JI, Ramsay E, Edwards K, Karlsson G, Bally MB. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation Design, pharmacokinetics and efficacy. J Control Release. 2011 Mar 10;150(2):212-9. PMID: 21094191 

Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, Overall CM, Minchinton A, Pacchiano F, Carta F, Scozzafava A, Touisni N, Winum JY, Supuran CT, Dedhar S. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011 May 1;71(9):3364-3376. Erratum in: Cancer Res. 2011 Jul 1:71(13):4733. Erratum in: Cancer Res. 2011. Jun 15;71(12):4325. PMID: 21415165 

Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strutt D, Osooly M, Masin D, Bally M. Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1:11(9):826-38. PMID: 21358264 

Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D,  Bally MB, Yapp DT. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (irinophore C), doxorubicin (Caelyx) or vincristine. BMC Cancer. 2011 Apr 8;11:124. PMID: 21477311 

Verreault M, Strutt D, Masin D, Fink D, Gill R, Bally MB. Development of glioblastoma cell lines expressing red fluorescence for non-invasive live imaging of intracranial tumors.  Anticancer Res. 2011 Jun;31(6):2161-71. PMID: 21737636 

Ho VW, Leung K, Hsu A, Luk B, Lai J, Shen SY, Minchinton AI, Waterhouse D, Bally MB, Lin W, Nelson BH, Sly LM, Krystal G. A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. Cancer Res. 2011;71(13):4484-93. PMID: 21673053 

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JHE, Kapanen AI, Kierkels GJJ, Masin D, Minchinton AI, Gelmon KA, Bally MB. The combination of Gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.   BMC Cancer. 2011 Oct; 11:420. PMID: 21961653 

 

2010

Banno B, Ickenstein LM, Chiu GN, Bally MB, Thewalt J, Brief E and Wasan EK.  The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo.  J Pharm Sci. 2010 May;99(5):2295-308. PMID: 19902527 

Ho EA, Ramsay E, Ginj M, Anantha M, Bregman I, Sy J, Woo J, Osooly-Talesh M, Yapp DT, Bally MB. Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties. J Pharm Sci. 2010 Jun;99(6):2839-53. PMID: 20091826 

Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release 2010 Jun 15; 144(3):332-40. PMID: 20202473 

Musende AG, Eberding A, Jia W, Ramsay E, Bally MB, Guns ET. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.  Prostate. 2010 Sept 15; 70(13): 1437-47. PMID: 20687217 

Kalra J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, Dunn SE, Bally MB. Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene. 2010 Dec 2;29(48):6343-56. PMID: 20838384 

 

2009

Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland B, Dedhar S, Gelmon K, Bally M. QLT0267, A Small Molecule Inhibitor Targeting Integrin-Linked Kinase (ILK), and Docetaxel Can Combine to Produce Synergistic Interactions Linked to Enhanced Cytotoxicity, Reductions in P-AKT levels, altered F-actin Architecture and Improved Treatment Outcomes in An Orthotopic Breast Cancer Model. Breast Cancer Res. 2009 May 1;11(3):R25. PMID: 19409087 

Musende A, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally M, Tomlinson Guns E. Pre-clinical Evaluation of Rh2 in PC-3 Human Xenograft Model for Prostate Cancer In vivo: Formulation, Pharmacokinetics, Biodistribution and Efficacy.  Cancer Chemother Pharmacol. 2009 Nov;64(6):1085-95. PMID: 19301006 

Verreault M, Bally MB. siRNA Mediated Integrin-Linked Kinase Suppression: Non-Specific Effects of siRNA/Cationic Liposome Complexes Trigger Changes in the Expression of Phosphorylated-AKT and mTOR Independently of ILK Silencing. Oligonucleotides. 2009 Jun; 19(2):129-40. PMID: 19284309 

Weiss A, Preston TC, Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB, Signorell R. Selective recognition of rituximab-functionalized gold nanoparticles by lymphoma cells studied with 3D imaging. The Journal of Physical Chemistry C. 2009 Oct 21;113(47):20252-8.

  

2008

Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D, Bally M. A Novel Liposomal Irinotecan Formulation with Significant Anti-tumor Activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.  Eur J Pharm. 2008 Mar;68(3):607-17. PMID: 17904831 

Woo J, Chiu GN, Karlsson G; Wasan EK, Ickenstein LM, Edwards K, Bally MB. Use of a Passive Equilibration Methodology to Encapsulate Cisplatin into Preformed Thermosensitive Liposomes.  Int J Pharm. 2008 Feb 12; 349(1-2):38-46. PMID: 17728083 

Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK).  Mol Cancer Ther. 2008 Jan;7(1):59-70. PMID: 18202010 

Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, Gorski SM. Macroautophagy Inhibition Sensitizes Tamoxifen-Resistant Breast Cancer Cells and Enhances Mitochondrial Depolarization. Breast Cancer Res Treat. 2008 Dec;112(3):389-403. PMID: 18172760 

McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell E, Bally MB, Foster L and  Dedhar S. Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylatin and Cancer Cell Survival. Cancer Res. 2008;68(6):1618-24. PMID: 18339839 

Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D, Bally MB. Irinophore CTM: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy Against a Panel of Human Xenograft Tumors Clin Cancer Res. 2008;14(4):1208-17. PMID: 18281556 

Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally M, Klasa RJ. Silencing Bcl-2 in Models of Mantle Cell Lymphoma Correlates with a Loss in Cyclin D1a Expression but not Cyuclin D1b and is Associated with Decreases in NFkappaB, p53, bax and p27 Levels. Molecular Cancer Therapy. 2008 Apr;7(4):749-58. PMID: 18375822 

Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB, Yapp DTT. Irinophore CTM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin.  Clin Cancer Res. 2008 Nov 15:14(22):7260-7l. PMID: 19010842    

 

2007

Ponce AM Viglianti BL Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally M, Dewhirst MW. Magnetic Resonance Imaging of Temperature-Sensitive Liposome Release: Drug Dose Painting and Antitumor Effects.  J National Cancer Institute. 2007 Jan 3;99(1):53-63. PMID: 17202113 

Tardi PG, Gallagher RC, Johnson S, Harasym N, Webb M, Bally MB, Mayer LD. Coencapsulation of Irinotecan and Floxuridine into Low Cholesterol Containing Liposomes that Coordinate Drug Release in Vivo. Biochim Biophys Acta. 2007 Mar;1768(3):678-87. PMID: 17208196 

Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. In vitro and in vivo Characterization of a Combination Chemotherapy Formulation Consisting of Vinorelbine and Phosphatidylserine. Eur J of Pharmaceutics and Biopharm. 2007;65:289-299. PMID: 17123800 

Chiu GNC, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KYY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of Cancer Cell Survival Pathways Using Multivalent Liposomal Therapeutic Antibody Constructs Mol Cancer Ther. 2007 Mar;6(3):844-855. PMID: 17339368 

Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased Levels of Hypoxic Cells in Gefitinib Treated ER+ HER-2 Overexpressing MCF-7 Breast Cancer Tumors Are Associated with Hyperactivation of the mTOR Pathway: Therapeutic Implications for Combination Therapy with Rapamycin.  Breast Cancer Res. Treat 2007 Dec; 106(3):319-31. PMID: 17347776 

Dos Santos N, Allen C, Doppen A-M, Anantha M, Cox KAK, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of Poly(ethylene Glycol) Grafting Density and Polymer Length on Liposomes: Relating Plasma Circulation Lifetimes to Protein Binding Biochim Biophys Acta. 2007 Jun; 1768(6):1367-77. PMID: 17400180 

Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, Bally MB. A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity. Letters in Drug Design & Discovery. September 2007;4(6):426-433. 

To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally M, Yapp D, Dunn SE. The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.  Mol Pharmacol. 2007 Sep;72(3):641-52. PMID: 17595327 

Webb MS, Rebstein P, Lamson W, Bally MB. Liposomal Drug Delivery: Recent Patents and Emerging Opportunities.  Recent Patents on Drug Delivery & Formulation. 2007. 1(3):185-94. PMID: 19075885 

Zastre J, Anantha M, Ramsay E, Bally M. Irinotecan-Cisplatin Interactions Assessed in Cell-Based Screening Assays: Cytotoxicity, Drug Accumulation and DNA Adduct Formation in an NSCLC Cell Line  Cancer Chemother Pharmacol. 2007 Jun;60(1):91-102. PMID: 17009029 

 

2006 

Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential Dependence of Breast Cancer Cells Versus Normal Cells on Integrin-Linked Kinase for PKB-AKT Activation and Cell Survival. Cancer Res. 2006;66(1):393-403. PMID: 16397254 

Tucker C, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally M. Williams ME. Four Human t(11;14)(q13;q32)-Containing Cell Lines Having Classic and Variant Features of Mantle Cell Lymphoma  Leuk Res. 2006 Apr;30(4):449-57. 

Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JHF, Dedhar S, Bally MB. Combined Inhibition of the Phosphatidylinosital 3-kinase/Akt and Ras/Mitogen- Activated Protein Kinase Pathways Results in Synergistic Effects in Glioblastoma Cells. Mol Cancer Ther. 2006;5(3):645-654. PMID: 16546979 

Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Zhang YZ, Yapp D, Dragowska V, Dunn S, Dedhar S. Bally MB. Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers. Current Cancer Drug Targets. 2006;6:455-489. PMID: 17017873 

Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric Dosing of Anticancer Drug Combinations: Controlling Drug Ratios After Systemic Administration Regulates Therapeutic Acitivity in Tumor-Bearing Mice.  Mol Cancer Ther. 2006;5(7):1854-63. PMID: 16891472 

Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally M. Copper-Topotecan Complexation Mediates Drug Accumulation into Liposomes  J. Controlled Release. 2006;114(1):78-88. PMID: 16842880 

Verreault M, Webb MS, Ramsay EC, Bally MB. Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems. Current Gene Therapy. 2006;6:505-533. PMID: 16918337 

Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in-vivo Tumor Liposomal Drug Concentration Using MRI. Magnetic Resonance in Medicine. 2006;56:1011-1018. PMID: 17029236 

Cogswell S, Berger SA, Waterhouse D, Bally MB, Wasan EK. A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model. Pharma Res. 2006 Nov;23(11):2575-2585. PMID: 17086505 

Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally M. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharma Res. 2006 Dec;23(12):2799-808. PMID: 17063397 

Chiu GNC, Harasym TO, Tardi PG, Bally MB, Waterhouse DN. Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB Family of Receptor Tyrosine Kinases: First Step in the Development of Therapeutic Antibody/Liposomal anticancer Drug Combinations. Letters in Drug Design and Discovery. 2006;3:704-713. 

Waterhouse DN, Bally MB. Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy. Future Medicine. 2006 Oct;1(3):359-63. PMID: 17716167 

 

2005

Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-Mutant Human Glioblastomas Inhibits PKB/Akt Activation, Induces Apoptosis, and Delays Tumor Growth  Oncogene. 2005;24:3596-3605. PMID: 15782140 

Chiu GN, Abraham SA, Ickenstein LM, Ng R, Karlsson G, Edwards K, Wasan EK, Bally MB. Encapsulation of Doxorubicin into Thermosensitive Liposomes via Complexation with the Transition Metal Manganese. J Control Release. 2005;104(2):271-288. PMID: 15907579 

Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial Increases in Idarubicin Plasma Concentration by Liposome Encapsulation Mediates Improved Antitumor Activity. J Control Release. 2005;105(1-2):89-105. PMID: 15878792 

Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and Liposomal Doxorubicin in the Treatment of MCF-7 Xenograft Tumor-Bearing Mice: Combination Does Not Affect Drug Serum Levels. Pharma Res. 2005 Jun;22(6):915-22. PMID: 15948035 

Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations. Current Drug Delivery. 2005 Oct;2(4):341-51. PMID: 16305437 

 

2004

Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In Vitro and In vivo Characterization of Doxorubicin and Vincristine Co-encapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading. Clin Cancer Res. 2004;10: 728-738. PMID: 14760096

Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biology and Therapy. 2004; 3(2):197-204. PMID: 14726684

Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol. Biochim Biophys Acta. 2004;1661:47-60. PMID: 14967474

Hu YP, Krishan A, Nie WJ, Sridhar KS, Mayer L, Bally M. Synergistic Cytotoxicity of Pyrazoloacridine with Doxorubicin, Etoposide and Topotecan in Drug Resistant Tumor Cells  Clin. Cancer Res. 2004;10(3):1160-9. PMID: 14871996

Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction.  Clin Cancer Res. 2004;10(7):2512-24. PMID: 15073131

Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An Evaluation of Transmembrane Ion Gradient-Mediated Encapsulation of Topotecan Within Liposomes. J Control Release. 2004; 96(3):449-461. PMID: 15120901

Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In-vivo Monitoring of Tissue Pharmacokinetics of Liposome/Drug Using MRI: Illustration of Targeted Delivery Magnetic Resonance in Medicine. 2004; 51:1153-1162. PMID: 15170835

Schutze-Redelmeier M-P M, Kong S, Bally MB, Dutz JP. Antennapedia Transduction Sequence Promotes Anti Tumour Immunity to Epicutaneously Administered CTL Epitopes. Vaccine. 2004;22(15-16):1985-91. PMID: 15121311

Edwards LA, Shabbits JA, Bally M, Dedhar S. Integrin-Linked Kinase (ILK) in Combination Molecular Targeting  Molecular. Targeting and Signal Transduction. 2004;119:59-75. PMID: 15164873

Messerer CL, Ramsay EC, Waterhouse DN, Ng R, Simms E-M, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal Irinotecan: Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer.  Clinical Cancer Research. 2004;10(19):6638-49. PMID: 15475454

Dragowska WH, Warburton C, Yapp DTT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization.  Mol Cancer Res. 2004;2(11):606-19. PMID: 15561777

Hu YP, Bebb G, Tan S, Ng R, Yan H, Mayer LD, Bally MB. Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non-Small Cell Lung Cancer  Clinical Cancer Research. 2004;10(22):7662-70. PMID: 15569999 

 

2003

Wong FM, Harvie P, Zhang YP, Ramsay EC, Bally MB.Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems. Int J Pharm. 2003;255(1-2):117-27. PMID: 12672608

Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier M-P. Effective Induction of CD8+ T-cell Response Using CpG Oligodeoxynucleotides and Her-2/Neu-Derived Peptide Co-Encapsulated in Liposomes. Vaccine. 2003; 21(23):3319-29. PMID: 12804863

Chiu GNC, Bally MB, Mayer LD. Targeting of Antibody Conjugated, Phosphatidylserine-Containing Liposomes to Vascular Cell Adhesion Molecule 1 for Controlled Thrombogenesis. Biochim Biophys Acta. 2003;1613(1-2):115-21. PMID: 12832092 

Hu Y, Bally M, Dragowska WH, Mayer LD. Inhibition of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Enhances Chemotherapeutic Effects on H460 Human Non-Small Cell Lung Cancer Cells through Activation of Apoptosis.  Mol Cancer Ther. 2003 Jul;2(7):641-9.  PMID: 12883037 

Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining Doxorubicin and Liposomal Anti-HER-2/NEU Antisense Oligodeoxynucleotides to Treat HER-2/NEU-Expressing MDA-MB-435 Breast Tumor Model. J Exp Ther Oncol. 2003;3(5):261-71. PMID: 14696623 

 

2002 

Li WM, Mayer LD, Bally MB. Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene glycol)-Modified Lipids. J Pharmacol Exp Therapeut. 2002;300(3):976-983. PMID: 11861806 

Chiu GNC, Bally MB, Mayer LD. Effects of Phosphatidylserine on Membrane Incorporation and Surface Protection Properties of Exchangeable Poly(ethylene glycol)-Conjugated Lipids. Biochim Biophys Acta. 2002;1560(1-2):37-50. PMID: 11958774 

Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer LD. Drug Interaction Studies Between Paclitaxel (Taxol) and OC144-093 - A New Modulator of MDR in Cancer Chemotherapy. Eur J Drug Metab Pharm. 2002; 27(2):119-126. PMID: 12064370 

Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KAK, Tardi PG, Bally MB. Improved Retention of Idarubicin after Intravenous Injection Obtained for Cholesterol-Free Liposomes.   Biochim Biophys Acta. 2002;1561:188-201. PMID: 11997119 

Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma Protein Binding, Lipoprotein Distribution and Uptake of Free and Lipid-Associated BCL-2 Antisense Oligodeoxynucleotides (G3139) in Human Melanoma Cells.  Int’l J of Pharmaceutics. 2002;241(1):57-64. PMID: 12086721 

Abraham SA, Edwards K, Karlsson G, MacIntosh S, Mayer LD, McKenzie C, Bally MB. Formation of Transition Metal-Doxorubicin Complexes Inside Liposomes. Biochim Biophys Acta. 2002; 565(1):41-54. PMID: 12225851

 Hu Q, Bally MB, Madden TD. Subcellular Trafficking of Antisense Oligonucleotides and Down-regulation of bcl-2 Gene Expression in Human Melanoma Cells Using a Fusogenic Liposome Delivery System. Nucleic Acids Res. 2002;30(16):3632-41. PMID: 12177306 

Allen C, Dos Santos N, Gallagher R, Chiu GNC, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the Physical Behavior and Biological Performance of Liposome Formulations through Use of Surface Grafted Poly(ethylene glycol). BioScience Reports. 2002;22(2):225-250. PMID: 12428902 

Chikh GG, Li WM, Schutze-Redelmeier M-P, Meunier J-C, Bally MB. Attaching Histidine-Tagged Peptides and Proteins to Lipid-Based Carriers Through Use of Metal-Ion-Chelating Lipids.  Biochim Biophys Acta. 2002;1567:204-212. PMID: 12488054 

Wong FMP, Macadam SA, Kim A, Oja C, Ramsay EC, Bally MB. A Lipid-Based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex. J of Drug Targeting. 2002 Dec;10(8):615-623. PMID: 12683666 

  

2001 

Chiu GNC, Bally MB, Mayer LD. Selective Protein Interactions with Phosphatidylserine Containing Liposomes Alter the Steric Stabilization Properties of Poly(ethylene glycol) Biochim Biophys Acta. 2001;1510:56-69. PMID: 11342147 

Wong M, Kong S, Dragowska V, Bally MB. Oxazole Yellow Homodimer YOYO-1-Labeled DNA: A Fluorescent Complex That Can Be Used to Assess Structural Changes in DNA Following Formation and Cellular Delivery of Cationic Lipid DNA Complexes Biochim Biophys Acta. 2001;1527:61-72. PMID: 11420144 

Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form: changing Toxicity Profiles. Drug Saf. 2001;24(12):903-920. Review.  PMID: 11735647 

Johnstone SA, Masin D, Mayer L, Bally MB, Surface Associated Serum Proteins Inhibit the Uptake of Phosphatidylserine and Poly(ethylene glycol) Liposomes by Mouse Macrophages  Biochim Biophys Acta. 2001;1513(1):25-37. PMID: 11427191 

Chikh G, Bally M, Schutze-Redelmeier M-P. Characterization of Hybrid CTL Epitope Delivery Systems Consisting of the Antennapedia Homeodomain Peptide Vector Formulated in Liposomes.  J Immuno Methods. 2001 Aug 1;254(1-2):119-35.  PMID: 11406158  

Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-Drug Interactions Arising from the Use of Liposomal Vincristine in Combination with Other Anti-Cancer Drugs Pharm. Res. 2001;18(9):1331-5. PMID: 11683249 

Hu Q, Shew CR, Bally MB and Madden TD,Programmable Fusogenic Vesicles for Intracellular Delivery of Antisense Oligodeoxynucleotides: Enhanced Cellular Uptake and Biological Effects Biochim Biophys Acta. 2001;514:1-13. PMID: 11513800 

Chikh G, Kong S, Bally M, Meunier JC, Schutze-Redelmeier M-P. Efficient Delivery of Antennapedia Homeodomain Fused to CTL Epitope with Liposomes into Dendritic Cells Results in the Activation of CD8+ T Cells.  J Immunology. 2001;167:6462-6470. PMID: 11714813 

Li WM, Xue L, Mayer LD, Bally MB. Intermembrane Transfer of Polyethylene Glycol Modified Phosphatidylethanolamine as a Means to Reveal Surface Associated Binding Ligands on Liposomes. Biochim Biophys Acta. 2001;1513:193-206. PMID: 11470091 

Guns ES, Bullock PL, Reimer MLJ, Dixon R, Bally M, Mayer LD. Assessment of the Involvement of CYP3A in the In Vitro Metabolism of a New Modulator of MDR in Cancer Chemotherapy, OC144-093, by Human Liver Microsomes. Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):273-82.  PMID: 11808870 

Li WM, Bally MB, Schutze-Redelmeier M-P. Enhanced Immune Response to T-Independent Antigen by Using CPG Oligonucleotides Encapsulated in Liposomes. Vaccine. 2001;20:148-157. PMID: 11567759 

  

2000 

Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. The Role of Drug Release and Liposome-Mediated Drug Delivery in Governing the Therapeutic Activity of Liposomal Mitoxantrone Used to Treat Human A431 and LS180 Solid Tumors. J Pharmacol Exp. Therapeutics. 2000;292(1):337-345. PMID: 10604968 

Harvie P, Wong FMP, Bally M. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci. 2000 May; 89(5):652-663. PMID: 10756331 

Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FMP. Eradication of Human Non-Hodgkin’s Lymphoma in SCID Mice by Bcl-2 Antisense Oligonucleotides Combined with Low Dose Cyclophosphamide. Clinical Cancer Res. 2000;6:2492-2500. PMID: 10873104 

Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In Vitro Characterization of the Anticancer Activity of Membrane-Active Cationic Peptides.  I. Peptide-mediated cytotoxicty and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anti-Cancer Drug Design. 2000;15:151-160. PMID: 10901303 

Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal Encapsulation of Topotecan Enhances Anticancer Efficacy in Murine and Human Xenograft Models. Cancer Res. 2000 Jul 1;60(13):3389-93. PMID: 10910044 

Mayer LD, Krishna R, Webb M,Bally MB. Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications. J Liposome Res. 2000;10(2&3):99-115. 

Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB. Kupffer Cells Do Not Play a Role in Governing the Efficacy of Liposomal Mitoxantrone Used to Treat a Tumor Model Designed to Assess Drug Delivery to Liver. Clinical Cancer Res. 2000;6:4449-4460. PMID: 11106266 

Saxon D, Chia SK, Bally MB. Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/NEU. Biological Therapy of Breast Cancer. 2000;1(3):7-11.  

 

1999 

Harasym TO, Bally MB, Tardi PG. Clearance properties of liposomes involving conjugated proteins for targeting.  Advanced Drug Delivery Reviews. 1999;32:99-118. PMID: 10837638 

Mayer LD, Reamer J, Bally MB. Intravenous Pretreatment with Empty pH Gradient Liposomes Alters the Pharmacokinetics and Toxicity of Doxorubicin through In Vivo Active Drug Encapsulation  J. Pharm Sci. 1999 Jan;88(1):96-102.  PMID: 9874708 

Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Burge C, Logan P, Mayer LD. A Phase I Study of Liposomal Vincristine.  J Clin Oncol. 1999;17(2):697-705. PMID: 10080616 

Reimer DL, Kong S, Monck M, Tam P, Wasan EK, Bally MB. Liposomal Lipid And Plasmid DNA Delivery to B16/BL6 Tumors After Intraperitoneal Administration of Cationic Liposome DNA Aggregates.  J. Pharmacol Exp Therapeutics. 1999;298(2):807-815. PMID: 10215656 

Wong FMP, Bally MB, Brooks DE.Electrostatically Mediated Interactions Between Cationic Lipid-DNA Particles and an Anionic Surface.  Archives of Biochemistry and Biophysics. 1999;366(1):31-39. PMID: 10334860 

Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled Destabilization of a Liposomal Drug Delivery System Enhances Mitoxantrone Antitumor Activity Nat Biotechnol. 1999 Aug; 17(8):775-9.  PMID: 10429242 

Bally MB, Harvie P, Wong FMP, Kong S, Wasan EK, Reimer DL. Biological Barriers to Cellular Delivery of Lipid-Based DNA Carriers. Advanced Drug Delivery Reviews. 1999;38(3):291-315. PMID: 10837762  

Wasan EK, Harvie P, Edwards K, Karlsson G, Bally MB.  A Multi-Step Lipid Mixing Assay to Model Structural Changes in Cationic Lipoplexes Used for In Vitro Transfection. Biochim Biophys Acta. 1999;1461:27-46. PMID: 10556486 

Saxon DN, Mayer LD, Bally MB. Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs. J Liposome Res. 1999;9:507-522. 

 

1998 

Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic Behavior of Vincristine Sulfate Following Administration of Vincristine Sulfate Liposome Injection Cancer Chemother. Pharmacol. 1998;41:347-352. PMID: 9523729 

Webb MS, Saxon D, Wong FMP, Lim HJ, Wang Z, Bally MB, Choi LSL, Cullis PR, Mayer LD. Comparison of Different Hydrophobic Anchors Conjugated to Poly(ethylene glycol): Effects on the Pharmacokinetics of Liposomal Vincristine Biochim Biophys Acta. 1998;1372:272-282. PMID: 9675310 

Webb MS, Logan P, Kanter PM, St.-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB, Preclinical Pharmacology, Toxicology and Efficacy of Sphingomyelin/Cholesterol Liposomal Vincristine for Therapeutic Treatment of Cancer Cancer Chemother. Pharmacol. 1998;42(6):461-470. PMID: 9788572 

Harvie P, Wong FMP, Bally MB. Characterization of Lipid DNA Interactions. I.  Destabilization of Bound Lipids and DNA Dissociation. Biophys J. 1998;75(2):1040-1051. PMID: 9675205 

Bally MB, Lim H, Cullis PR, Mayer LD. Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations. J Liposome Res. 1998;8(3):299-335. 

Wasan EK, Fairchild A, Bally MB. Cationic Liposome-Plasmid DNA Complexes Used for Gene Transfer Retain a Significant Trapped Volume. J Pharm Sci. 1998 Jan; 87(1):9-14. PMID: 9452961 

 

1997 

Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma Clearance, Biodistribution and Therapeutic Properties of Mitoxantrone Encapsulated in Conventional and Sterically Stabilized Liposomes after Intravenous Administration in BDF1 Mice.  British J Cancer, 1997;75(2):169-177. PMID: 9010021 

Bally MB, Zhang Y-P, Wong FMP, Kong S, Wasan E, Reimer DL. Lipid/DNA Complexes as an Intermediate in the Preparation of Particles for Gene Transfer: An Alternative to Cationic Liposome/DNA Aggregates Advanced Drug Delivery Reviews. 1997;24(2-3):275-290. 

Zhang YP, Reimer DL, Zhang G, Lee PH, Bally MB. Self-Assembling DNA-Lipid Particles for Gene Transfer Pharmaceutical Res. 1997;14(2):190-196. PMID: 9090708 

Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of Liposomal Lipid and Encapsulated Doxorubicin in Murine Lewis Lung Carcinoma:  The Lack of Beneficial Effects by Coating Liposomes with Poly(Ethylene Glycol). J Pharmacol Exp Therapeutics. 1997;280(3):1319-1327. PMID: 9067319 

Mayer LD, Dougherty G, Harasym TO, Bally MB. The Role of Tumour-Associated Macrophages in the Delivery of Liposomal Doxorubicin to Solid Murine Fibrosarcoma Tumours. J Pharmacol Exp Therapeutics. 1997;280 (3):1406-1414. PMID: 9067330 

Lim HJ, Masin D, Madden TD, Bally MB.  Influence of Drug Release Characteristics on the Therapeutic Activity of Liposomal Mitoxantrone J. Pharmacol Exp Therapeutics. 1997; 281(1):566-573. PMID: 9103545 

Reimer DL, Kong S, Bally MB. Analysis of Cationic Liposome-mediated Interactions of Plasmid DNA with Murine and Human Melanoma Cells in Vitro. J Biol Chem. 1997;272(31):19480. PMID: 9235950  

Reimer DL, Bally MB, Singh SM. Human gene therapy: Principles and modern advances Biotechnology Ann Rev. 1997, 3:59-110. 

Harasym TO, Cullis PR, Bally MB. Intratumor Distribution of Doxorubicin Following i.v. Administration of Drug Encapsulated in Egg Phosphatidylcholine/Cholesterol Liposomes. Cancer Chemotherapy Pharmacology. 1997;40:309-317. PMID: 9225948 

Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Webb M, Bally M, Mayer LD. Validation of a High-Performance Liquid Chromatographic Assay Method for Quantification of Total Vincristine Sulfate in Human Plasma Following Administration of Vincristine Sulfate Liposome Injection.  J Pharmaceut Biomed Anal. 1997;16:675-687. PMID: 9502163 

Bally MB, Ansell SM, Tardi PG, Harasym TO. Liposome Targeting Following Intravenous Administration:  Defining Expectations and a Need for Improved Methodology. J Liposome Res. 1997;7(4):331-361. 

Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB. An Immune Response to Ovalbumin Covalently Coupled to Liposomes Is Prevented When the Liposomes Used Contain Doxorubicin. J Immunol Meth. 1997;210:137-148. PMID: 9520297 

Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH Gradients on the Transbilayer Transport of Drugs, Lipids, Peptides and Metal Ions into Large Unilamellar Vesicles Biochim Biophys Acta. 1997;1331:187-211. PMID: 9325441 

 

1996 

Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine Induced Dermal Toxicity Is Significantly Reduced When the Drug Is Given in Liposomes.  Cancer Chemotherapy Pharmacol. 1996;37 (4):351-5. PMID: 8548881 

Wong FMP, Reimer DL, Bally MB. Cationic Lipid Binding to DNA  Characterization of Complex Formation. Biochemistry. 1996;35(18):5756-5763. PMID: 8639536 

Wasan EK, Reimer DL, Bally MB. Plasmid DNA Is Protected Against Ultrasonic Cavitation-Induced Damage When Complexed to Cationic Liposomes.  J Pharmaceutical Sci. 1996;85:427-433. PMID: 8901083 

Silver HKB, Klasa RJ, Bally MB. Genetic Allogenization of Malignant Melanoma. Transfus. Sci. 1996;17(1):169-174.  

 

1995 

Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of Liposomal Vincristine in Mice Bearing L1210 Ascitic and B16/BL6 Solid Tumours. British J Cancer. 1995; 71:482-488. PMID: 7880728 

de Jong G, Gelmon K, Bally M, Goldie J, Mayer L. Modulation of Doxorubicin Resistance in P388/ADR cells by Ro44-5912, a Tiapamil Derivative. Anticancer Res. 1995 May-Jun;15(3):911-916.  PMID: 7645981 

Longman SA, Cullis PR, Choi L, de Jong G, Bally MB. A Two-Step Targeting Approach for Delivery of Doxorubicin-Loaded Liposomes to Tumour Cells In Vivo Cancer Chem. Pharmacol. 1995;36:91-101. PMID: 7767956 

Redelmeier TE, Guillet J-G, Bally MB. High Affinity Targeting of Biotin Labeled Liposomes to Streptavidin Conjugated Ligands  Drug Delivery. 1995;2:98-109. 

Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LSL. Polyethylene Glycol Modified Phospholipids Prevent Aggregation During Covalent Conjugation of Proteins to Liposomes.  Bioconjugate Chemistry. 1995;6:187-194. PMID: 7599262 

Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-Cholesterol Liposomes Significantly Enhance the Pharmacokinetic and Therapeutic Properties of Vincristine in Murine and Human Tumour Models. British J Cancer. 1995;72:896-904. PMID: 7547237 

Webb MS, Wheeler JJ, Bally MB, Mayer LD. The Cationic Lipid Stearylamine Reduces the Permeability of The Cationic Drugs Verapamil and Prochlorperazine to Lipid Bilayers:  Implications for Drug Delivery.  Biochim Biophys Acta. 1995;1238:147-155. PMID: 7548129 

Reimer DL, Zhang YP, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of Novel Hydrophobic Complexes Between Cationic Lipids and Plasmid DNA. Biochemistry. 1995;34:12877-12883. PMID: 7548044 

Longman SA, Cullis PR, Bally MB. A Model Approach for Assessing Liposome Targeting in vivo. Drug Delivery. 1995;2:156-165. 

Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB. Accumulation of Protein-Coated Liposomes in An Estravascular Site: Influence of Increasing Carrier Circulation Lifetimes. Journal of Pharmacology and Experimental Therapeutics. 1995;275:3;1177-1184. PMID: 8531079 

Boman NL, Bally MB, Cullis PR, Mayer LD, Webb MS. Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy.  J Liposome Res. 1995;5:523-541. 

Choice E, Masin D., Bally MB, Meloche M, Madden TD. Liposomal Cyclosporine:  Comparison of Drug and Lipid Carrier Pharmacokinetics and Biodistribution. Transplantation. 1995;60:1006-1011. PMID: 7491673 

 

1994 

Mayer LD, Cullis PR, Bally MB. The Use of Transmembrane pH Liposomal Doxorubicin  J. Liposome Res. 1994;4:529-553.  

Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Transfer of Liposomal Drug Carriers From the Blood to the Peritoneal Cavity of Normal and Ascitic Tumor Bearing Mice. Cancer Chemotherapy Pharmacol. 1994;34:137-146. PMID: 8194164 

Boman NL, Masin D, Cullis PR, Bally MB. Liposomal Vincristine Which Exhibits Increased Drug Retention and Increased Circulation Longevity Cures Mice Bearing P388 Tumors. Cancer Res. 1994;54:2830-2833. PMID: 8187061 

Kanter PM, Klavich GM, Ballard GA, Jim JM, Bally MB, Mayer LD. Liposome Encapsulated Vincristine:  Preclinical Toxicologic and Pharmacologic Comparison with Free Vincristine and Empty Liposomes in Mice, Rats and Dogs Anticancer Drugs, 1994;5: 579-590. PMID: 7858291 

Wheeler JJ, Wong KF, Ansell S, Masin D, Bally MB. Polyethylene Glycol Modified Phospholipids Stabilize Microemulsions Prepared from Triacylglycerol. J Pharma. Sci. 1994;83:1558-1564. PMID: 7891274 

 

1993 

Parr MJ, Bally MB, Cullis PR. The Presence of GM1 in Liposomes with Entrapped Doxorubicin Does not Prevent RES Blockade. Biochim Biophys Acta. 1993;1168:249-252. PMID: 8504161 

Mayer LD, Nayer R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of Vesicle Properties Which Enhance the Antitumour Activity of Liposomal Vincristine Against Murine L1210 Leukemia. Cancer Chemother Pharmacol. 1993;33:17-24. PMID: 8269584 

 

1991 

Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH Gradients and Membrane Transport in Liposomal Systems.  Trends in Biotechnology. 1991;9:268 272. PMID: 1367566 

 

1990 

Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CPS, Reinish LW, Cullis PR. The Accumulation of Drugs Within Large Unilamellar Vesicles Exhibiting a Proton Gradient: A Survey Chem. Phys. 1990;Lipids 53:37 46. PMID: 1972352 

Mayer LD, Tai LCL, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of Liposomal Systems Containing Doxorubicin Entrapped in Response to pH Gradients  Biochim Biophys Acta. 1990;1025:143 151. PMID: 2364073 

Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with Entrapped Doxorubicin Exhibit Extended Blood Residence Times. Biochim Biophys Acta. 1990;1023:133 139. PMID: 2317492 

Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal Vincristine Preparations Which Exhibit Decreased Drug Toxicity and Increased Antitumour Activity Against Murine L1210 and P388 Tumors.  Cancer Res. 1990 Feb 1:50(3):575 579.  PMID: 2297698 

Loughrey HC, Choi L, Cullis PR, Bally MB. Optimized Procedures for the Coupling of Proteins to Liposomes.  J Immunological Methods. 1990;132:25-35. PMID:2391438 

Loughrey HC, Wong KF, Choi L, Cullis PR, Bally MB. Protein Liposome Conjugates With Defined Size Distributions Biochim Biophys Acta. 1990;1028:73 81. PMID:2207121 

Loughrey HC, Bally MB, Reinish LW, Cullis PR. The Binding of Phosphatidylglycerol Liposomes to Rat Platelets is Mediated by Complement Thrombosis and Haemostasis. 1990; 64:172 176. PMID: 2274922 

Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the Myelosuppressive Activity of Doxorubicin Entrapped in Liposomes Cancer Chemotherapy and Pharmacology. 1990; 27:13 19. PMID: 2245488 

Thies RL, Cowens W, Cullis PR, Bally MB, Mayer LD. Method for Rapid Separation of Liposome Associated Doxorubicin from Free Doxorubicin in Plasma Anal. Biochem. 1990;188:65-71. PMID: 2221370 

Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of Free and Liposome Encapsulated Doxorubicin Tumor Drug Uptake and Antitumor Efficacy in the SC115 Murine Mammary Tumor.  Cancer Letters. 1990;53:183 190. PMID: 2208078 

Mayer LD, Bally MB, Cullis PR. Strategies for Optimizing Liposomal Doxorubicin J. Liposome Res. 1990;1:463 480.

  

1989 

Balazsovits J, Mayer LD, Bally MB, Cullis PR, Ginsberg RS, Falk R. Analysis of the Effect of Liposome Encapsulation on the Vesicent Properties, Acute and Cardiac Toxicities and Antitumour Efficacy of Doxorubicin. Cancer Chemotherapy and Pharmacology 1989;23:81 86. PMID: 2491964 

Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet Distribution in Rabbits Following Infusion of Liposomes. Thrombosis and Haemostasis. 1989;61(3):392 396. PMID: 2799754 

Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR. Proton transport in large unilamellar vesicles in response to electrical potentials and pH gradients  Biophys. J. 1989;56:385 393. PMID: 2775833 

Mayer LD, Tai LC, Ko DSC, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of Vesicle Size, Lipid Composition and Drug to Lipid Ratio on the Biological Activity of Liposomal Doxorubicin. Cancer Research. 1989;49:5922 5930. PMID: 2790807 

Cullis PR, Mayer LD, Bally MB, Madden TD, Hope MJ. Generation and Loading of Liposomal Systems for Drug Delivery Application. Advanced Drug Delivery Review. 1989;3:267 282. 

 

1988

Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan R, Hope MJ, Cullis PR. Dopamine Accumulation in Large Unilamellar Vesicle Systems by Transmembrane ion Gradients Chem. Phys. Lipids. 1988;47:97 107. PMID: 2457454 

Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of Liposomes and Platelets Thromb Haemost. 1988 Dec 22;60(3):518 523. PMID: 3238654 

 

1987

Loughrey H, Bally MB, Cullis PR. A Novel Covalent Method of Attaching Antibodies to Liposomes. Biochem Biophys Acta. 1987 Jul 10;901(1)157-60.  PMID: 3593723 

 

1986

Mayer LD, Bally MB, Cullis PR. Uptake of Adriamycin into Large Unilamellar Vesicles in Response to a pH Gradient.  Biochim Biophys Acta. 1986;857:123-126. PMID: 3964703 

Hope MJ, Bally MB, Mayer LD, Janoff AS, Cullis PR. Generation of Multilamellar and Unilamellar Phospholipid Vesicles. Chem Phys. 1986;Lipids 40:89-108. 

Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for Encapsulating Bioactive Agents into Liposomes. Chem Phsy Lipids. 1986;40:333-346. PMID: 3742676 

 

1985

Shertzer HG, Bally MB, Opheim DJ. Inhibition of Alveolar Macrophage Killing by Di(2 ethylhexyl) Phthalate  Arch. Environ. Contam. Toxicol. 1985;(5): 605-608. PMID: 4051570 

Hope MJ, Bally MB, Webb G, Cullis PR. Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure: Characterization of Size, Trapped Volume and Ability to Maintain a Membrane Potential  Biochim Biophys Acta. 1985 Jan 10;812(1):55-65.  PMID: 23008845 

Bally MB, Hope MJ, van Echteld CJA, Cullis PR. Uptake of Safranine and Other Lipophilic Cations into Vesicles in Response to a Membrane Potential  Biochim Biophys Acta. 1985;812:66-76. 

Mayer LD, Bally MB, Hope MJ,Cullis PR. Uptake of Dibucaine into Large Unilamellar Vesicles in Response to a Membrane Potential.  J Biol Chem. 1985;260:802-808. PMID: 3968068 

Mayer LD, Bally MB, Hope MJ,Cullis PR. Uptake of Antineoplastic Agents into Large Unilamellar Vesicles in Response to a Membrane Potential  Biochim Biophys Acta. 1985;816:294-302. PMID: 3839135 

Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. Protection of Large Unilamellar Vesicles by Trehalose During Dehydration: Retention of Vesicle Contents. Biochim Biophys Acta. 1985;817:67-74. PMID: 4005259 

Thomas P, Bally MB, Neff JM. Influence of Some Environmental Variables on the Ascorbic Acid Status of Mullet (Mugil Cephalus Linn.) Tissues II. Seasonal Fluctuations and Biosynthetic Ability J. Fish Biol. 1985;27:47-57. 

 

1984 

Tilcock CPS, Bally MB, Farren SB, Cullis PR, Gruner SM. Cation Dependent Segregation Phenomena and Phase Behaviour in Model Membrane Systems Containing Phosphatidylserine: Influence of Cholesterol and Acyl Chain Composition Biochem. 1984;23:2696-2703. PMID: 6466608 

 

1983 

Bally MB, Tilcock CPS, Hope MJ, Cullis PR. Polymorphism of Phosphatidylethanolamine Phosphaditylserine Model Systems: Influence of Cholesterol and Mg2+ on the Ca2+  Triggered Bilayer to Hexagonal (Hii) Transition  Can. J. Biochem. 1983;61:346-352. PMID: 6883167 

Carr RS, Bally MB, Thomas P, Neff JM. Comparison of Methods for Determination of Ascorbic Acid in Animal Tissues  Anal. Chem. 1983;55:1229-1232. PMID: 6614490  

 

1982

Thomas P, Bally MB, Neff JM. Ascorbic Acid Status of Mullet Exposed to Cadmium. J Fish Biology. 1982; 20:183-186.

Tilcock CPS, Bally MB, Farren SB, Cullis PR. Influence of Cholesterol on the Structural Preferences of Dioleoylphosphatidylethanolamine Dioleoylphosphatidyl¬choline Systems: A31p and 2H NMR Study Biochemistry. 1982;21:4596 4601. PMID: 7138819

  

1980

Bally MB, Opheim DJ, Shertzer HG. Di(2 Ethylhexyl) Phathalate Enhances the Release of Lysosomal Enzymes from Alveolar Macrophages During Phagocytosis. Toxicology. 1980;18:49-60. PMID: 7210023

 

 

Non-Peer Reviewed Papers 

 

2004 

Bally MB, Tardi P, Harasym T, Harasym N, Swenson C, Janoff A and Mayer LD. (2004).  Spotlight Celator Technologies. Controlled Release Society Newsletter, 21(2), 11.

 

 

Books and Chapters 


2015 

Kalra J, Yapp DT, Webb M and Bally MB (2015)  “Applications for drug development”  In: “Handbook of Small Animal Imaging: Preclinical Imaging, Therapy, and Applications” (GC Kagadis, NL Ford, DN Karnabatidis, GK Loudos, Ed), Taylor and Francis Group (In Press)

 

2011 

Verreault M, Yip S, Toyota B and Bally MB (2011) "The potential and challenges of siRNA-based targeted therapy for treatment of patients with glioblastoma" In: "Glioma / Book 3", ISBN 979-953-307-198-4  (Faris Farassati, Ed),  Intech Open Access Publisher; Chapter 9; 161-188.

 

2008 

Waterhouse DN, Kalra J, Verreault M, Ramsay E, Dragowska W, Yapp D, Webb M, Chiu G and Bally MB (2008)  “Nanotechnology as an Enabling Approach to the Development of Fixed-Dose Combination Products for Treating Cancer”  In:  Handbook of Particulate Drug Delivery, Vol.2: Applications, pp.11-39  (M.N.V. Ravi Kumar, Ed), American Scientific Publishers

 

2006 

Harasym TO, Tardi PG, Johnstone SA, Mayer LD, Bally MB and Janoff AS (2006)  “Fixed Drug Ratio Liposome Formulations of Combination Cancer Therapeutics”  In:  Liposome Technology Third Edition, Vol.III, Interactions of Liposomes with the Biological Milieu, pp.25-48 (G. Gregoriadis, Ed), Informa Healthcare USA, Inc.

 

2005 

Wasan EK, Gleave M, Fang K, Chi K, Bebb G, Edwards L and Bally MB (2005)  “Docetaxel for Metastatic Cancer and Its Role in Combination Therapies for Advanced Prostate Cancer” In: Bone Metastasis: Experimental and Clinical Therapeutics, pp. 255-294 (G. Singh and S.A. Rabbani, Ed), Humana Press, Totowa, NJ. 

Waterhouse DN, Bally MB, Mayer LD, Madden TD, Cullis PR and Webb MS (2005)  “Preparation, Characterization and Biological Analysis of Liposomal Formulations of  Vincristine”  In: Methods in Enzymology, Vol.391, Liposomes, Part E, pp.40-57 (N. Duzgunes, Ed), Elsevier Academic Press. 

Abraham SA, Waterhouse DN, Mayer L, Cullis P, Madden T and Bally MB (2005)  “Liposomal Formulations of Doxorubicin”  In: Methods in Enzymology, Vol.391, Liposomes, Part E, pp.71-97 (N. Duzgunes, Ed), Elsevier Academic Press.

 

2001 

Mayer LD, Krishna R and Bally, MB (2001) “Liposomes for Cancer Therapy Applications”  In: Polymeric Biomaterials, 2nd Edition (S. Dumitriu, ed.) Marcel Dekker (New York, NY), 823-841. 

Tardi P, Ickenstein L, Bally M and Mayer LD (2001) “The Development of Liposomes for Enhanced Delivery of Chemotherpeutics to Tumors” In: Cancer Drug Discovery and Development: Tumor Targeting in Cancer Therapy, pp. 119-135 (M. Pagé, Ed), Humana Press Inc., Totowa, NJ.

 

2000 

Wasan EK, Reimer DL, Harvie P, Kong S, Wong FMP and Bally MB (2000) “Targeted Gene Transfer: A Practical Guide Based on Experience with Lipid-Based Plasmid Delivery Systems”  In: Methods in Molecular Medicine, Vol. 25: Drug Targeting: Strategies, Principles, and Applications, pp. 255-304 (G.E. Francis and C. Delgado, Ed.), Humana Press Inc., Totowa, NJ. 

Ansell SM, Harasym TO, Tardi PG, Buchkowsky SS, Bally MB and Cullis PR (2000)  “Antibody Conjugation Methods for Active Targeting of Lipsomes” ”  In: Methods in Molecular Medicine, Vol. 25: Drug Targeting: Strategies, Principles, and Applications, pp. 51-68 (G.E. Francis and C. Delgado, Ed.), Humana Press Inc., Totowa, NJ.

 

1998 

Mayer LD, Cullis PR and Bally MB (1998)  “Designing Therapeutically Optimized Liposomal Anticancer Delivery Systems: Lessons from Conventional Liposomes”  In:  Medical Applications of Liposomes, pp. 231-257 (DD Lasic and D Papahadjopoulos, Ed.), Elsevier, N.Y. 

 

1997 

Boman NL, Cullis PR, Mayer LD, Bally MB and Webb MS (1997) “Liposomal Vincristine:  The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations”  In:  Long Circulating Liposomes: Old Drugs, New Therapeutics, 29-49. 

 

1995 

Boman NL, Cullis PR, Bally MB and Mayer LD (1995) “Preclinical and Clinical Activity of Liposomal Doxorubicin”  In: Liposomes in Biomedical Applications, (PN Shek, Ed.), 85-103. 

Mayer LD, Gelmon K, Cullis PR, Boman N, Webb MS, Embree L, Tolcher T and Bally MB (1995) “Preclinical and Clinical Studies With Liposomal Vincristine” In: Progress in Drug Delivery System, Vol. 4, pp. 151-161, Biomedical Research Foundation, Tokyo. 

 

1993 

Loughrey HC, Choi LS, Wong KF, Cullis PR and Bally MB  (1993)  “Preparation of Streptavidin Liposomes for use in Ligand Specific Targeting Applications” In: Liposome Technology: 2nd Edition, (G Gregoriadis, Ed.), Vol. 3, Pp. 163-178, CRC Press, Inc., Boca Raton, FL. 

Bally MB, Mayer LD, Hope MJ and Nayar R (1993) “Pharmacodynamics of Liposomal Drug Carriers: Methodological Considerations”  In: Liposome Technology: 2nd Edition, (G Gregoriadis, Ed.), Vol. 3, Pp. 27-42, CRC Press, Inc., Boca Raton, FL. 

Mayer LD, Bally MB, Madden TD and Cullis PR  (1993)  “Transmembrane pH Gradient Driven Drug Loading Procedure” In: Liposome Technology: 2nd Edition, (G Gregoriadis, Ed.), Vol. 2, Pp. 27-44, CRC Press, Inc., Boca Raton, FL.

 

1988 

Bally MB, Hope MJ, Mayer LD, Madden TD and Cullis PR (1988) “Novel Procedures for Generating and Loading Liposomal Systems” In: Liposomes As Drug Carriers: Recent Trends and Progress, (G Gregoriadis, Ed.), John Wiley and Sons, New York, Pp. 841 853.

 

1987

Cullis PR, Hope MJ, Bally MB, Janoff AS, Madden TD and Mayer LD (1987) “Liposomes As Pharmaceuticals” In: Liposomes, (M Ostro, Ed.), Marcel Dekker, New York, Pp. 39 72.

 

1982

Cullis PR, De Kruiff B, Hope MJ, Verkleij AJ, Nayar R, Farren SB, Tilcock CPS, Madden TD and Bally MB (1982) “Structural Properties of Lipids and Their Functional Roles in Biological Membranes” In: Membrane Fluidity, Volume 2, (RC Aloia, Ed.), Academic Press, New York, Pp. 39 81.